BioSpace News Archive

Cerevel Therapeutics, a biopharmaceutical company focused on developing new medicines to treat disorders of the central nervous system (CNS), today announced the publication of results from a Phase 2a study1 in Neurology demonstrating the anticonvulsant activity of CVL-865 (formerly PF-06372865), a novel α2/3/5-subtype selective GABAA positive allosteric modulator, in patients with photosensitive epilepsy (seizures triggered by visual stimuli).

FHI Clinical manages complex clinical research in resource-limited settings around the world

As part of his role at VeraSci, he will assist in the implementation of the trials of both relapsing and progressive forms of multiple sclerosis (MS).

Children’s Hospital of Philadelphia (CHOP) announced today that Beverly L. Davidson, PhD, CHOP’s Chief Scientific Strategy Officer and Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, has been elected Vice President of the Board of Directors for the American Society of Gene and Cell Therapy (ASGCT), the largest association of individuals involved in gene and cell therapy research.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of five new global grants programs to continue to support investigator-sponsored research in chronic hepatitis C virus (HCV) and hepatitis B virus (HBV), HCV and HIV co-infection, nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC)

VolitionRx Limited hosted a Capital Markets Day at the New York Stock Exchange to update interested parties on its recent progress.

Built on Google Cloud Platform, the BrightInsight Platform supports and optimizes regulated drugs, devices and software through integrated data and actionable insights

Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Synergy Pharmaceutical, Inc. against certain of the Company’s current and former officers and directors.

Pomerantz LLP announces that a class action lawsuit has been filed against Akorn, Inc. and certain of its officers and directors.

Second study, REMfresh Patient Reported Outcomes DURation (REMDUR), peer-reviewed and presented at a major sleep medicine conference, SLEEP 2018, provided confirmatory real-world evidence of the 7-hour action of REMfresh.